Current or prior use of immunosuppressive medication within  days before the first dose of their assigned IP; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or its equivalent \r\n* Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan pre-medication)
The use of immunosuppressive medication within  days prior to the first dose of nivolumab; the following are exceptions to this criterion:\r\n* Intranasal, topical, inhaled corticosteroids or local steroid injections (e.g. intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)
Subjects with medical conditions that require the chronic use of systemic corticosteroids; exceptions include: inhaled, intranasal, ophthalmic, and topical corticosteroids, local corticosteroid injections (e.g., intra-articular injections), and subjects requiring corticosteroid pre-medication for hypersensitivity reactions (e.g. CT scan premedication)
Current or prior use of immunosuppressive medication within  days before the first dose of durvalumab and tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, and topical steroids\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
EXCLUSION - DURVALUMAB DRUG-SPECIFIC: Current or prior use of immunosuppressive medication within  days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed  mg/day of prednisone, or an equivalent corticosteroid. The following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
Current or prior use of immunosuppressive medication within  days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication).
Current or prior use of immunosuppressive medication within  days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
Current use of immunosuppressive medication, except for the following:\r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
Current use of immunosuppressive medication, except for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
Current use of immunosuppressive medication, EXCEPT for the following:\r\n* Topical, ocular, intra-articular, intranasal, and inhaled corticosteroids.\r\n* Systemic corticosteroids at physiologic doses =<  mg/day of prednisone equivalent.\r\n* Steroids as premedication for hypersensitivity reactions
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent: * Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible \r\n* Current use of immunosuppressive medication, EXCEPT for the following: \r\n** Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); \r\n** Systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent; \r\n** Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication).
Systemic treatment with either immunosuppressive doses of corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration\r\n* Subjects on a standard high-dose steroid taper after craniotomy or stereotactic biopsy may have received a higher dose of corticosteroids within  days of registration, however must be at a dose <  mg daily prednisone or bioequivalent per day within  days prior to initiation of study drug\r\n* Administration of steroids through a route known to result in a minimal systemic exposure (i.e., intranasal, intraocular, inhaled, topical, or local injection [e.g., intra-articular injection] corticosteroids [< % of body surface area]) are permitted in the absence of active autoimmune disease\r\n* Subjects requiring adrenal replacement with corticosteroids are eligible if the steroids are at doses =<  mg prednisone or bioequivalent per day in the absence of active autoimmune disease\r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication) are allowed
Current use of immunosuppressive medication, except for the following: \r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses ?  mg/day of prednisone or equivalent \r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
Current or prior use of immunosuppressive medication within  days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
Current use of immunosuppressive medication, EXCEPT for the following:\r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g. intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)
Current or prior use of immunosuppressive medication(s) within  days before study treatment is NOT permitted; the following are EXCEPTIONS to this criterion and are allowed\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication).
Current or prior use of immunosuppressive medication within  days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed << mg/day>> of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)\r\n* Receipt of live attenuated vaccine within  days prior to the first dose of IP; Note: patients, if enrolled, should not receive live vaccine whilst receiving IP and up to  days after the last dose of IP
Current use of immunosuppressive medication, except for the following: \r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection) \r\n* Systemic corticosteroids at physiologic doses ?  mg/day of prednisone or equivalent \r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
Current usage of immunosuppressant medication except for a) intranasal, inhaled, and topical corticosteroids and b) systemic corticosteroids equivalent to =<  mg/day of prednisone, c) steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)
Current or prior use of immunosuppressive medication within  days prior to the first dose of durvalumab; the following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (eg. intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed mg/day of prednisone or equivalent; (NOTE: If systemic corticosteroids are part of the treatment regimen for the indication under study, the systemic corticosteroid is permitted)
Current use of immunosuppressive medication, EXCEPT for the following:\r\n* Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (eg, intra-articular injection); b. systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
Subjects with diagnosis of immunodeficiency or who are receiving systemic steroid therapy or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment; the following are exceptions to this exclusion criteria: intranasal, inhaled, topical steroids, or local steroids injections (e.g. intra-articular injection); systemic corticosteroids at physiologic dose not to exceed  mg/day of prednisone or equivalent; steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
Immunosuppressive medication within  days prior to the first dose of study treatment; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least  days\r\n* Systemic corticosteroids at physiologic doses of <  mg/day of prednisone or equivalent
Current or prior use of immunosuppressive medication within  days prior to the first dose of MEDI or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
Current or prior use of immunosuppressive medication within  days before the first dose of investigational product (IP). The following are exceptions to this criterion:  Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)  Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or its equivalent  Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
Current or prior use of immunosuppressive medication within  days before the first dose of durvalumab and tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or its equivalent\r\n* Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan pre-medication)
Intranasal, inhaled, or topical steroids or local steroid injections (eg, intra-articular injection) are permitted;
Steroids as premedication for hypersensitivity reactions are permitted;
Subject is currently using or has used immunosuppressive medication within  days prior to the first dose of study treatment; the following are exceptions:\r\n* Intranasal, topical, inhaled, or local steroid injections (e.g., intra-articular injection)\r\n* Chronic systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reaction (e.g., infusion-related reactions, computed tomography [CT] scan premedication)
Current or prior use of systemic immunosuppressive medication within  days before the first dose of durvalumab + trabectedin, with the exception of systemic corticosteroids at physiological doses, which are not to exceed  mg/day of prednisone, or an equivalent corticosteroid; the following are exceptions to this criterion:\r\n* Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
Immunosuppressive medication within  days prior to day  of protocol therapy; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least  days\r\n* Systemic corticosteroids at physiologic doses of <  mg/day of prednisone or equivalent
Current or prior use of immunosuppressive medication within  days prior to first dose of durvalumab; the following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (eg. intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed mg/day of prednisone or equivalent
Intranasal, inhaled, topical or local steroid injections (eg, intra-articular injection);
Steroids as premedication for hypersensitivity reactions (eg, computed tomography (CT) scan premedication);
Intranasal, inhaled, topical, or local steroid injections (eg, intra-articular injection)
Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
Current or prior use of immunosuppressive medication within  days prior to first dose of durvalumab; the following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (eg. intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed  mg/day of prednisone or equivalent; (NOTE: If systemic corticosteroids are part of the treatment regimen for the indication under study, the systemic corticosteroid is permitted)
Use of immunosuppressive medications within  days before the first dose of study drug; the following are exceptions to this criterion: intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection); systemic corticosteroids at physiological doses not to exceed mg/day of prednisone or its equivalent; steroids as premedication for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)
Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
Current or prior use of immunosuppressive medication within  days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
Current use of immunosuppressive medication, except for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
The use of immunosuppressive medication within  days prior to the first dose of durvalumab; the following are exceptions to this criterion:\r\n* Intranasal, topical, inhaled corticosteroids or local steroid injections (e.g. intraarticular injection)\r\n* Systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)
Current or prior use of immunosuppressive medication within  days prior to enrollment with the following exceptions to this exclusion criterion: \r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
Current or prior use of immunosuppressive medication within  days before the first dose of durvalumab or tremelimumab; the following are exceptions to this criterion:\r\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\r\n* Systemic corticosteroids at physiologic doses not to exceed << mg/day>> of prednisone or its equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
Subject is currently using or has used immunosuppressive medication within  days prior to the study agent administration; the following are exceptions:\r\n* Intranasal, topical, inhaled, or local steroid injections (e.g., intra-articular injection)\r\n* Chronic systemic corticosteroids at physiologic doses not to exceed  mg/day of prednisone or equivalent\r\n* Steroids as premedication for hypersensitivity reactions (e.g., infusion-related reactions, CT scan premedication)
Current or prior use of immunosuppressive medication within  days prior to first vaccine; the following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (e.g. intra-articular injection); steroids as premedication for hypersensitivity reactions; systemic corticosteroid at physiologic doses not to exceed  mg/day of prednisone or equivalent
Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
Patients with evidence of significant intracranial mass effect that requires >  mg of dexamethasone or bioequivalent per day for  consecutive days for management of symptoms at any time within  days of registration\r\n* Subjects on a standard high-dose steroid taper after craniotomy may receive a higher dose of corticosteroids within  days of registration, however must be at a dose =<  mg of dexamethasone or bioequivalent per day within  days prior to registration\r\n* Administration of steroids through a route known to result in a minimal systemic exposure (i.e., intranasal, intraocular, inhaled, topical, or local injection [e.g., intra-articular injection] corticosteroids [< % of body surface area]) are permitted\r\n* Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are at doses =<  mg prednisone or bioequivalent per day\r\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) are allowed